Article
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers.
Cell reports. Medicine - 19 Aug 2025
Theardy Madelaine S, Takeda Mitsunobu, Sorokin Alexey, Chen Shuaitong, Yang Zecheng, Wang Xiaofei, Kanikarla Preeti, Coker Oluwadara, Nguyen Phuoc, Wei Yongkun, Yao Jun, Yan Liang, Jin Yanqing, Cai Yiming, Paku Masakatsu, Chen Ziheng, Li Kara Z, Citron Francesca, Tomihara Hideo, Gao Sisi, Deem Angela K, Zhao Jun, Wang Huamin, Hanash Samir, DePinho Ronald A, Maitra Anirban, Draetta Giulio F, Ying Haoqiang, Kopetz Scott, Yao Wantong
Abstract excerpt
The therapeutic benefit of recently developed mutant KRAS (KRAS∗) inhibitors remains limited by the rapid onset of resistance. Here, we aim to delineate mechanisms underlying acquired resistance and identify actionable targets for overcoming this clinical challenge. Previously, we identified syndecan-1 (SDC1) as a key effector for pancreatic cancer progression whose surface expression is driven by KRAS∗. By...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.